VeriChip Unveils Plans For Self-Contained Implantable RFID Glucose-Sensing Microchip

Delray Beach, FL - VeriChip Corporation, a provider of RFID systems for healthcare and patient-related needs, and its project partners Digital Angel Corporation ("Digital Angel") and Receptors LLC recently unveiled details, including plans to build a prototype self-contained implantable bio-sensing device included in an RFID microchip (the "Microchip"), that for the first time will have the ability to measure glucose levels in the human body. Millions of patients with diabetes utilize needle sticks to monitor levels of glucose on a daily basis. Through the Microchip, patients are expected to be able to track glucose levels without the constant invasive and painful effect of a needle. Prior to the event, the Company will issue a "white paper" describing the features, benefits and technology underlying the development of its revolutionary self-contained implantable glucose-sensing device.

According to the Centers for Disease Control and Prevention (CDC), as of 2005 diabetes affects nearly 21 million Americans – or 7 percent of the U.S. population, including an additional 2.6 million people with diabetes since 2002. Another 41 million people are estimated to have pre-diabetes, a condition that increases the risk of developing type 2 diabetes – the most common form of the disease – as well as heart disease and stroke.

Scott R. Silverman, Chairman and CEO of VeriChip Corporation, stated, "Upon complete development, this technology can change the lives of patients with diabetes, providing them with a convenient way to monitor their blood-sugar levels. Today, the common method involves a prick of the finger. Our self-contained sensor can change that and negate the need for daily invasive testing. This system will allow for one injection every 4-6 months (approximate) that permits the diabetic to externally scan the device and retrieve a blood sugar reading as often as necessary."

SOURCE: Digital Angel Corporation